Piramal Pharma LimitedNSE: PPLPHARMA

Press Release Oct 23 2024

· Issued by Piramal Pharma Limited

Filed with NSE · · 30 pages · English

Summary by 6ix AI

The company reported a year-on-year revenue increase driven by strong performance in its Contract Development and Manufacturing Organization (CDMO) segment. Additionally, Piramal Pharma is planning a substantial expansion at its Lexington facility to enhance its sterile fill-finish capabilities. The results reflect the company's commitment to sustainability and its long-term financial goals.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Piramal Pharma Limited has informed the Exchange regarding a press release dated October 23, 2024, titled "Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended 30th September, 2024".

Piramal Pharma Limited on 6ix

In the deck

Earlier from Piramal Pharma

Later from Piramal Pharma

All Piramal Pharma news releases